Surmelioglu, N. Et Al. 2024. Favipiravir pharmacokinetics in COVID-19 patients with moderate to severe kidney dysfunction: Lessons learned for future use. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS , vol.62, no.8 , 345-352.

Surmelioglu, N., DEMİRTÜRK, E., Ayhan, N. A., Yesilyurt, A. O., Bayrakci, S., KAYNAK, M. S., ... Ozyilmaz, E.(2024). Favipiravir pharmacokinetics in COVID-19 patients with moderate to severe kidney dysfunction: Lessons learned for future use. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS , vol.62, no.8, 345-352.

Surmelioglu, Nursel Et Al. "Favipiravir pharmacokinetics in COVID-19 patients with moderate to severe kidney dysfunction: Lessons learned for future use," INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS , vol.62, no.8, 345-352, 2024

Surmelioglu, Nursel Et Al. "Favipiravir pharmacokinetics in COVID-19 patients with moderate to severe kidney dysfunction: Lessons learned for future use." INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS , vol.62, no.8, pp.345-352, 2024

Surmelioglu, N. Et Al. (2024) . "Favipiravir pharmacokinetics in COVID-19 patients with moderate to severe kidney dysfunction: Lessons learned for future use." INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS , vol.62, no.8, pp.345-352.

@article{article, author={Nursel Surmelioglu Et Al. }, title={Favipiravir pharmacokinetics in COVID-19 patients with moderate to severe kidney dysfunction: Lessons learned for future use}, journal={INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS}, year=2024, pages={345-352} }